Shanghai Moyang Biotechnology Completes New Round of Financing, Accelerating Expansion into New Opportunities in the Medical Aesthetics Industry
Recently, Shanghai Moyang Biotechnology Co., Ltd. announced the successful completion of a new round of financing worth hundreds of millions of yuan. This round of financing attracted participation from well-known domestic investment institutions such as a leading domestic fund, Huagai Capital, and Lanchi Ventures, providing strong momentum for Moyang Biotechnology's continued development in the field of regenerative biomaterials. This will accelerate the commercial deployment of core products like the Youfalan™ Magic CC Needle, offering solid support in production, sales, and brand building, as well as robust financial backing for the company's R&D innovation, market expansion, and global strategy.
The funds from this financing will primarily be used to expand the marketing team, enhance global market coverage, accelerate the R&D of next-generation products, and advance Moyang Biotechnology's industrial layout in the regenerative medical aesthetics sector, helping it move swiftly toward its goal of becoming a "leading enterprise in the field of regenerative medical aesthetics."
Moyang Biotechnology will also take this financing as an opportunity to uphold its mission of "returning medical aesthetics to its medical essence," continuing to drive product applications with innovative technology and providing more rigorous and professional services for doctors and beauty seekers. The company aims to contribute more to the "New China Manufacturing" in China's reconstructive field and offer more competitive Chinese solutions to the global medical aesthetics market.
The new investors in this round have each achieved notable success in the investment field and possess unique and precise judgment on high-growth-potential enterprises. They not only have a broad layout in the consumer healthcare industry but also deep industry understanding and successful investment cases. Their participation not only provides Moyang Biotechnology with ample financial support but also, leveraging their rich industry resources and strategic vision, is expected to help the company achieve leapfrog development in key areas such as product iteration, market expansion, and brand elevation, accelerating its transition from an industry leader to a global benchmark.
Regarding the addition of new shareholders in this financing, Lin Guangming, Chairman of Moyang Biotechnology, stated: "The support from our new shareholders is a high recognition of Moyang Biotechnology's achievements in the field of regenerative biomaterials and a firm confidence in the future potential of the medical aesthetics industry. These investors have profound resources and extensive successful experience in the healthcare sector. They not only bring strong financial support but will also inject new momentum into our product iteration, market expansion, and brand upgrade with their precise industry insights and extensive resource networks.
With this collaboration, Moyang Biotechnology will accelerate the global commercial deployment of core products like the Youfalan™ Magic CC Needle, further enhancing its market penetration in the regenerative medical aesthetics field. At the same time, with the support of the new shareholders, we can more efficiently advance the R&D of next-generation products and consolidate our global leading position in the precise control technology of CaHA materials. In the future, we will work hand in hand with our shareholders to drive industry upgrades with innovative technology under the mission of 'returning medical aesthetics to its medical essence,' not only to the 'New China Manufacturing' for the Chinese medical aesthetics market but also to provide competitive Chinese solutions globally, seizing new opportunities in the regenerative medical aesthetics industry and moving swiftly toward the goal of becoming a 'leading enterprise in the field of regenerative medical aesthetics.'"
Investors' Perspectives Focus on Technology and Market
The investment institutions participating in this round shared their investment logic based on their respective research:
A leading domestic fund's consumer sector head stated: Hydroxyapatite (CaHA) is a regenerative material applied in the global medical aesthetics market. The Moyang Biotechnology team has years of experience in biomedical material R&D, deep technical accumulation, and a diversified technology platform combining hydrogel and microspheres. As the first product in the hydroxyapatite field to obtain a Class III medical device registration certificate (for medical aesthetics indications) from China's National Medical Products Administration (NMPA), Youfalan™ has demonstrated commercial potential. The fund is optimistic about Moyang Biotechnology's forward-looking layout and future development prospects.
Huagai Capital's team stated: This investment is primarily based on recognition of the professionalism and dedication of founder Mr. Lin Guangming and his team. Moyang Biotechnology has long been committed to product R&D, and its innovative "raspberry-like mesoporous microsphere structure" design achieves precise control of hydroxyapatite microsphere particle size (30-35μm), porosity (74%), and the number of microspheres per unit volume (35 million/ml), earning the product China's first Class III medical device registration certificate for medical aesthetics indications. Moyang Biotechnology's products have also obtained medical device registration certificates in regions such as the EU and the Middle East.
Lanchi Ventures' team stated: They have observed that China's medical aesthetics industry is transitioning from sales-driven to product-value-driven, with sustained demand for innovative and effective products. At the same time, China's participation in global R&D for the medical aesthetics industry is increasing. Moyang Biotechnology, with its systematic R&D platform, has demonstrated technical capabilities in its existing product pipeline and forward-looking layout. Lanchi Ventures participated in this round of financing to support the company in expanding its technological boundaries and jointly drive industry innovation.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
